Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.87)
# 577
Out of 4,778 analysts
100
Total ratings
61.4%
Success rate
5.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $71.56 | +25.77% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $508.99 | -5.70% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $59.20 | -7.09% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $107.88 | -25.84% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $9.17 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $634.07 | +60.08% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $306.76 | +32.03% | 2 | Oct 22, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $281.02 | -21.71% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $8.67 | +15.34% | 5 | Sep 16, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $5.23 | +24.28% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $40.88 | +76.13% | 1 | Apr 13, 2023 |
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $71.56
Upside: +25.77%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $508.99
Upside: -5.70%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $59.20
Upside: -7.09%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $107.88
Upside: -25.84%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $9.17
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $634.07
Upside: +60.08%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $306.76
Upside: +32.03%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $281.02
Upside: -21.71%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $8.67
Upside: +15.34%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.23
Upside: +24.28%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $40.88
Upside: +76.13%